Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Hanwha Offers Up to $1.2 Billion for Austal US Business 
Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
Trump Media Says Truth API Draws 10+ Customers as Conflict Concerns Grow 
Airbus Joins Air India A320 Altitude Drop Probe 
JPMorgan Plans More Asia-Pacific Hiring in 2027 as Corporate Banking Revenue Surges 
US Judge Dismisses Gautam Adani Criminal Charges 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
MOUNTAIN VIEW, Calif., Feb. 20, 2018 -- Amunix Operating Inc. (Amunix), a biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapeutics, is pleased to announce that it has entered into a licensing agreement with Celgene. The agreement allows for the utilization of Amunix’s proprietary XTEN and ProTIA technology to augment ongoing discovery and development of therapeutics with the potential for improved delivery, enhanced safety, targeted delivery, and half-life attributes against specified targets selected by Celgene.
Volker Schellenberger, PhD, CEO of Amunix commented: “We are extremely pleased by the decision made by the Celgene team in selecting Amunix’s XTEN and ProTIA technologies to further enhance the development of its therapeutic drug pipeline. We look forward to future milestone achievements in the development of novel entities from the collaborative effort between our companies.” Geller Biopharm, Inc. served as Amunix’s exclusive agent for this licensing agreement.
About Amunix:
Amunix, based in Mountain View, CA, is a privately held biotechnology company with two proprietary technologies, XTEN and ProTIA. XTEN is a half-life extension technology is based on hydrophilic, unstructured, biodegradable proteins that impart a number of favorable properties upon the molecules to which they are attached. In addition to the advantages of reduced dosing frequency, XTENylation stabilizes plasma drug concentrations, which often results in increased efficacy as well as reduced side effects. Amunix has licensed this technology to numerous companies in a wide range of therapeutic areas. Two genetically fused XTENylated products have been clinically tested.
ProTIAs are bispecific molecules that bind tumor antigens and T cells. ProTIAs are administered as long-acting prodrugs that can be activated in the tumor environment by tumor-associated proteases. Amunix is developing internally a pipeline of ProTIA-based (Protease Triggered Immune Activator) immuno-oncology therapeutics, as well as offering partners access to the ProTIA technology for augmenting the safety and efficacy of their molecules. For additional information about the company, please visit www.amunix.com.
Contact:
Volker Schellenberger, Ph.D.
President and CEO
Tel: 650-889-5095
[email protected]
